fda reconsiders tirzepatide The says the Zepbound shortage is over. That's rattling the weight loss industry FDA confirms tirzepatide shortage is

Liraglutide 3 mg (Saxenda) a once-daily GLP-1 receptor agonist licensed for obesity management (NICE TA664)

However, because the science is new, there is not a lot to confirm its application in humans

GLP-1s are injectable medications with real side effects we wont rank a provider highly just because theyre cheap if their sourcing is questionable

Starting slowly and increasing activity as tolerated is especially important during early treatment or dose escalation periods

Ji L, Agesen RM, Bain SC et al (2024) Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial